Pulmonary diseases caused by non-tuberculous mycobacteria

European Respiratory Monograph

Volumn 58, Issue , 2012, Pages 25-37

  van Ingen, Jakko ^a   Griffith, David E ^b   Aksamit, Timothy R ^c   Wagner, Dirk ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^c Mayo Clinic   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Lung disease; Mycobacterium abscessus; Mycobacterium avium; Mycobacterium intracellulare; Mycobacterium xenopi; Non tuberculous mycobacteria

Indexed keywords

EID: 84870844856     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10022511     Document Type: Article

References (95)

1. van Ingen J, Bendien SA, de Lange WC, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009; 64: 502-506.
2. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
3. Bodle EE, Cunningham JA, Della-Latta P, et al. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 2008; 14: 390-396.
4. Cassidy PM, Hedberg K, Saulson A, et al. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49: e124-e129.
5. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010; 182: 970-976.
6. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010; 182: 977-982.
7. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010; 16: 1576-1583.
8. Marras TK, Chedore P, Ying AM, et al. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax 2007; 62: 661-666.
9. Tsai CF, Shiau MY, Chang YH, et al. Trends of mycobacterial clinical isolates in Taiwan. Trans R Soc Trop Med Hyg 2011; 105: 148-152.
10. Billinger ME, Olivier KN, Viboud C, et al. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg Infect Dis 2009; 15: 1562-1569.
11. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007; 176: 306-313.
12. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-a therapy. Emerg Infect Dis 2009; 15: 1556-1561.
13. Andrejak C, Nielsen RB, Thomsen V, et al. Chronic respiratory disease, inhaled corticosteroids and risk of nontuberculous mycobacteriosis. Thorax 2012; [Epub ahead of print DOI: 10.1136/thoraxjnl-2012-201772].
14. van Ingen J, Wagner D. Epidemiologie der nichttuberkulösen mykobakteriellen Erkrankungen in Deutschland und weltweit [The epidemiology of nontuberculous mycobacterial disease in Germany and worldwide]. Der Pneumologe 2011; 8: 396-403.
15. Simons S, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011; 17: 343-349.
16. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002; 23: 553-567.
17. Falkinham JO III. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009; 107: 356-367.
18. Falkinham JO III. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011; 17: 419-424.
19. Romanus V, Hallander HO, Wahlen P, et al. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis 1995; 76: 300-310.
20. Tremblay V, Ayad T, Lapointe A, et al. Nontuberculous mycobacterial cervicofacial adenitis in children: epidemiologic study. J Otolaryngol Head Neck Surg 2008; 37: 616-622.
21. Trnka L, Dankova D, Svandova E. Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tuber Lung Dis 1994; 75: 348-352.
22. Hoefsloot W, van Ingen J, de Lange WC, et al. Clinical relevance of Mycobacterium malmoense isolation in the Netherlands. Eur Respir J 2009; 34: 926-931.
23. van Ingen J, Boeree MJ, de Lange WC, et al. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis 2008; 46: 1200-1205.
24. van Ingen J, de Zwaan R, Dekhuijzen RP, et al. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009; 59: 324-331.
25. van Ingen J, Boeree MJ, de Lange WC, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008; 14: 385-389.
26. van Ingen J, Hoefsloot W, Buijtels PC, et al. Characterization of a Mycobacterium chimaera variant. J Med Microbiol 2012; 61: 1234-1239.
27. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183: 405-410.
28. Martin-Casabona N, Bahrmand AR, Bennedsen J, et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004; 8: 1186-1193.
29. Shitikov E, Ilina E, Chernousova L, et al. Mass spectrometry based methods for the discrimination and typing of mycobacteria. Infect Genet Evol 2012; 12: 838-845.
30. Leao SC, Tortoli E, Euzeby JP, et al. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61: 2311-2313.
31. van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15: 149-161.
32. Kobashi Y, Yoshida K, Miyashita N, et al. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother 2006; 12: 195-202.
33. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007; 101: 130-138.
34. Kobashi Y, Abe M, Mouri K, et al. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 2012; 18: 436-443.
35. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by Mavium intracellulare, Mmalmoense, and Mxenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56: 167-172.
36. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160: 866-872.
37. Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996; 153: 1766-1772.
38. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. 2nd Edn. Wayne, CLSI, 2011.
39. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-317.
40. Ahn CH, Wallace RJ Jr, Steele LC, et al. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am Rev Respir Dis 1987; 135: 10-16.
41. Wallace RJ Jr, Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994; 18: 736-743.
42. Wallace RJ Jr, Swenson JM, Silcox VA, et al. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152: 500-514.
43. Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52: 565-571.
44. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-1376.
45. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119: 107-159.
46. Evans SA, Colville A, Evans AJ, et al. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Thorax 1996; 51: 1248-1252.
47. Jenkins PA, Campbell IA. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. Respir Med 2003; 97: 439-444.
48. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321: 863-868.
49. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101: 1605-1609.
50. Wilde O. Lady Windermere's Fan. 1892.
51. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-1278.
52. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37: 1178-1182.
53. Valero G, Peters J, Jorgensen JH, et al. Clinical isolates of Mycobacterium simiae in San Antonio, Texas. An 11-yr review. Am J Respir Crit Care Med 1995; 152: 1555-1557.
54. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178: 1066-1074.
55. Ziedalski TM, Kao PN, Henig NR, et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006; 130: 995-1002.
56. Kim JS, Tanaka N, Newell JD, et al. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. Chest 2005; 128: 3863-3869.
57. Polverosi R, Guarise A, Balestro E, et al. High-resolution CT of nontuberculous mycobacteria pulmonary infection in immunocompetent, non-HIV-positive patients. Radiol Med 2010; 115: 191-204.
58. Khoor A, Leslie KO, Tazelaar HD, et al. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol 2001; 115: 755-762.
59. Aksamit TR. Hot tub lung: infection, inflammation, or both? Semin Respir Infect 2003; 18: 33-39.
60. Marras TK, Wallace RJ Jr, Koth LL, et al. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 2005; 127: 664-671.
61. Hanak V, Kalra S, Aksamit TR, et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir Med 2006; 100: 610-615.
62. Centers for Disease Control and Prevention. Respiratory illness in workers exposed to metalworking fluid contaminated with nontuberculous mycobacteria - Ohio, 2001. MMWR Morb Mortal Wkly Rep 2002; 51: 349-352.
63. Glazer CS, Martyny JW, Lee B, et al. Nontuberculous mycobacteria in aerosol droplets and bulk water samples from therapy pools and hot tubs. J Occup Environ Hyg 2007; 4: 831-840.
64. Hanak V, Golbin JM, Ryu JH. Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis. Mayo Clin Proc 2007; 82: 812-816.
65. Hartman TE, Jensen E, Tazelaar HD, et al. CT findings of granulomatous pneumonitis secondary to Mycobacterium avium-intracellulare inhalation: "hot tub lung". AJR Am J Roentgenol 2007; 188: 1050-1053.
66. Martinez S, McAdams HP, Batchu CS. The many faces of pulmonary nontuberculous mycobacterial infection. AJR Am J Roentgenol 2007; 189: 177-186.
67. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 828-834.
68. Olivier KN, Weber DJ, Lee JH, et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167: 835-840.
69. Roux AL, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol 2009; 47: 4124-4128.
70. Griffith DE. Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 810-812.
71. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756.
72. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121: 3554-3563.
73. Cattamanchi A, Nahid P, Marras TK, et al. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 2008; 133: 875-880.
74. Kalayjian RC, Toossi Z, Tomashefski JF Jr, et al. Pulmonary disease due to infection by Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1995; 20: 1186-1194.
75. Torriani FJ, McCutchan JA, Bozzette SA, et al. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis 1994; 170: 1601-1605.
76. van Ingen J, Boeree MJ, van Ingen J, et al. Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? Infect Genet Evol 2012; 12: 832-837.
77. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIVinfected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41: 1483-1497.
78. Riddell J, Kaul DR, Karakousis PC, et al. Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl Med 2007; 5: 50.
79. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38: 1428-1439.
80. Daley CL. Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant 2009; 14: 619-624.
81. Weinstock DM, Feinstein MB, Sepkowitz KA, et al. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. BoneMarrow Transplant 2003; 31: 1015-1021.
82. Tsukamura M. Diagnosis of disease caused by Mycobacterium avium complex. Chest 1991; 99: 667-669.
83. Sugihara E, Hirota N, Niizeki T, et al. Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MAC) infection. J Infect Chemother 2003; 9: 328-332.
84. Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1997; 155: 2041-2046.
85. Taillard C, Greub G, Weber R, et al. Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey. J Clin Microbiol 2003; 41: 1240-1244.
86. van Ingen J, Boeree MJ, Dekhuijzen PN, et al. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J 2008; 31: 106-109.
87. Andrejak C, Thomsen VO, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181: 514-521.
88. Koh WJ, Lee JH, Kwon YS, et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest 2007; 131: 1825-1830.
89. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174: 928-934.
90. Wallace RJ Jr, Zhang Y, Brown-Elliott BA, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002; 186: 266-273.
91. Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2012; 25: 218-227.
92. van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012; 186: 559-565.
93. Mitchell JD, Bishop A, Cafaro A, et al. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg 2008; 85: 1887-1892.
94. van Ingen J, Verhagen AF, Dekhuijzen PN, et al. Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. Int J Tuberc Lung Dis 2010; 14: 99-105.
95. Yu JA, Pomerantz M, Bishop A, et al. Lady Windermere revisited: treatment with thoracoscopic lobectomy/ segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur J Cardiothorac Surg 2011; 40: 671-675.